Celcuity Soars 112.27% on Positive Breast Cancer Trial Results

On July 28, 2025, Celcuity's stock surged by 112.27% in pre-market trading, marking a significant milestone for the company.

Celcuity has recently announced clinically meaningful improvements in both progression-free survival (PFS) primary endpoints from the PIK3CA wild-type cohort of its Phase 3 trial. This breakthrough is particularly noteworthy as it demonstrates the efficacy of the company's treatment in a specific patient population, which could have substantial implications for future clinical strategies and patient outcomes.

The positive results from the Phase 3 trial have been a key driver of investor optimism. The trial, which focused on breast cancer treatment, showed statistically significant improvements in PFS, indicating that the treatment combinations tested are effective in delaying disease progression. This news has been well-received by the market, as it validates the company's research and development efforts and positions Celcuity as a leader in innovative cancer treatments.

Celcuity's announcement of positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial further solidifies its position in the market. The results indicate that the combination of gedatolisib and fulvestrant reduced the risk of disease progression, providing a promising new option for patients with this specific genetic mutation. This development is crucial as it addresses an unmet medical need and offers hope to patients who may not have responded to traditional therapies.